Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. - Wikidata - wikimedia - TriplyDB

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.

http://www.wikidata.org/entity/Q34448370

about

Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease Statin therapy and autoimmune disease: from protein prenylation to immunomodulation Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity Pharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signalling Therapeutic decisions in multiple sclerosis: moving beyond efficacy New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics Statin treatment in multiple sclerosis: a systematic review and meta-analysis.PEG minocycline-liposomes ameliorate CNS autoimmune disease.Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair.Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation.Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis.Metabolic Control of Th17 Cell Generation and CNS Inflammation The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alon Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration.Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study SIRT1 activation confers neuroprotection in experimental optic neuritis Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis.Glatiramer acetate treatment negatively regulates type I interferon signaling.Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.Systems-based medicine approaches to understand and treat complex diseases. The example of multiple sclerosis.Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2.Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.Statins--treatment option for central nervous system autoimmune disease?Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity.Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis.Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.CD11c+CD11b+ dendritic cells play an important role in intravenous tolerance and the suppression of experimental autoimmune encephalomyelitis Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis.Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.Combinatorial Effect of Metformin and Lovastatin Impedes T-cell Autoimmunity and Neurodegeneration in Experimental Autoimmune Encephalomyelitis.Regulation of different inflammatory diseases by impacting the mevalonate pathway.Direct and consensual murine pupillary reflex metrics: establishing normative values Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins.Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.Cholesterol: a novel regulatory role in myelin formation.Statins as modulators of regulatory T-cell biology.Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet.B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

P2860

Q21135577-B65B5133-D678-4C5A-B3C1-2CD1A97094AE Q28236647-1FB65F05-8646-46DD-A710-7B6D207C2843 Q28308287-8E4F42AA-B24F-4044-B2D4-46FD68E47B48 Q28481922-41AF0E6C-E91C-490B-A9C6-713EF11D5B9B Q28506096-96C76FB3-25B9-44AF-94D2-1C5EEA0BC45E Q28541039-03EE9E05-BB76-485B-80FD-E9CBCE1B43BE Q30371980-1D7F03EB-3C1C-412B-AB28-68EE5121745F Q30913423-89FCE1A1-5A43-4371-B34C-82D02A44B253 Q33398048-2F2DD0B1-C79E-47CF-9624-D301147ADE13 Q33610240-F76795CB-121D-4637-B1DC-033659B73E49 Q34055604-1587134D-0D22-4E8A-BBCF-A8AA5A4B7769 Q34109028-11EF1F06-7A5B-4C4F-9FAF-1CD29498306A Q35101158-0A7C8C4C-A185-427D-9B12-B0CEF5980344 Q35276609-6EF712B9-A2D2-4386-8F68-EE0B624413DE Q35838945-A78AC0BC-0BC7-44CF-9D63-768608E093D8 Q35872344-118653BC-923F-4A16-A388-F3FC27AF482D Q35971418-95124EAA-1B11-4A95-95EB-7D86D97143FA Q36204144-895B8574-5348-4E8F-8DCA-745D3A3A0669 Q36280868-9CA99C7D-B6D0-46FB-BEC3-8FF9CBF5DD39 Q36598778-20A743A6-CDC3-44A1-B5DE-429FACFBF664 Q36687908-F74BEEF2-DE1C-434F-BE3A-DCC17AF279B1 Q36817063-A713C957-E242-4989-8ABD-59D1D1158FC0 Q36866185-A45B8898-FA0F-473D-9948-D1E6457084FE Q36963184-51D0426C-DD60-4C6C-B79F-DE712A767EA2 Q36963213-75D42ED0-A28B-4E08-96A2-682A1A2D1DF9 Q36973680-D9259185-3355-4BAC-BEA1-BD91C53CB804 Q37084467-DF7CFDD3-D601-4195-B51B-6792918CEB8D Q37139712-C66A2388-0892-4CF7-BB7D-F09D9B0D43E5 Q37178367-286A4927-2B84-4D55-83A1-C14D1E2BEDBE Q37253314-D7D8B4AE-CCC9-4701-861B-AC3F60433A17 Q37318146-3B2CE52B-8A04-4050-BD90-4EA9BE37B181 Q37373698-194C44B5-CDD5-4831-B763-290B5AE9ED15 Q37385042-9A02C2F3-B012-4280-9BA0-A33327170C69 Q37518236-CD50684A-D011-43B8-9CE5-FEFBCD798733 Q37543452-277B516D-B9C7-419C-8E1E-7B0091677EBD Q37580266-5CB7E826-7E49-4262-AF03-B6A905A5F9EA Q37846006-3772DAC1-35C7-4451-97BC-3A4643479352 Q38162189-8FB756EF-F457-4E23-BD27-156EF95E8D52 Q38261618-EEBF444A-CF68-4A8C-80CC-43EC50B34C42 Q38795434-B3B094B3-D5F4-45B6-BCD3-5EA2F995A423

P2860

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.

http://www.wikidata.org/entity/Q34448370

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@ast

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@en

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@nl

type

label

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@ast

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@en

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@nl

prefLabel

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@ast

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@en

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@nl

P1433

Q34448370-4C7D530E-2ABC-43E9-A47D-5C30C2A11830

P1476

Q34448370-1E0720C8-8FC4-47FC-BF2F-A6D06B40B18C

P2093

Q34448370-037C7B6D-D3A3-47B8-AA16-65C0BF1257F1

Q34448370-152CC226-92FA-4B58-AB54-E92A1B85D9A7

Q34448370-44B367F8-7231-473C-A1A3-185815C56A6B

Q34448370-5213A739-F706-4F16-8A5E-052C5AF4DE56

Q34448370-AE6BA5FE-EDE3-48CD-B30C-E6D5A34EBB71

Q34448370-BE1F21D4-37B9-4485-ABB5-B2AE059610B3

Q34448370-CE40428E-AD90-46A6-8A0A-24F17891AD06

Q34448370-CE4FA697-5448-4CB4-B8AC-1F13BF637D79

Q34448370-EFDF87FB-12A5-4ECA-A7D1-B56AD6CF979D

P2860

Q34448370-045D5326-A311-4F7F-9E98-2D09D2289847

Q34448370-05247F26-D71C-4F20-92F4-944E38878D8E

Q34448370-0A7D3C70-B3BE-4E25-A14A-DE45734CDF9E

Q34448370-0EF52C10-8DD8-44F5-A37B-1B48CCD844AA

Q34448370-15C56B23-D151-44E4-A2FB-57416C0234BD

Q34448370-1B07A0DB-3716-4BF3-AF5F-DFC5B44A05EA

Q34448370-1D8662F5-7E91-4290-A2D5-C81E78977EF6

Q34448370-2B158EBE-35D6-44FE-B43F-E159DD9E19E0

Q34448370-2E23FB8E-21F8-4C62-B535-A13F44591C9D

Q34448370-39175EB8-91DF-477E-852E-E8F7B1C75A7C

P304

Q34448370-AE0CE3A5-C1CD-4C41-8EB3-A6E12798FD5C

P31

Q34448370-50A239AF-6D8A-4F9D-97DE-730CE7CA0724

P356

Q34448370-7CE4EE98-124D-4F48-B312-AB5399770222

P407

Q34448370-4FA19743-E01A-4398-9EEB-786C1D5AEF9B

P433

Q34448370-A64CD7B4-8444-4C70-8CB2-BA1BD5298B81

P478

Q34448370-829683DE-6DCC-4A85-9CEC-EA07DB1D9B39

P50

Q34448370-08873046-1297-4E9D-98E1-F0F50370ED8C

P577

Q34448370-E5BA5A99-77B1-4915-B1ED-EA2F560AFAA7

P5875

Q34448370-FED85B9D-E1F1-49CB-BEA8-631E78B3070F

P698

Q34448370-E44152EE-5DF4-41F6-B30E-D5C27E418258

P932

Q34448370-E8AC4964-C2EC-4BA4-8D1C-234ADF848428

P356

P1433

Journal of Clinical Investigation

P1476

Immunomodulatory synergy by co ...... treatment of CNS autoimmunity.

@en

P2093

Bernhard Hemmer

http://www.w3.org/2001/XMLSchema#string

Hans-Christian von Büdingen

http://www.w3.org/2001/XMLSchema#string

Lawrence Steinman

http://www.w3.org/2001/XMLSchema#string

Martin S Weber

http://www.w3.org/2001/XMLSchema#string

Raymond A Sobel

http://www.w3.org/2001/XMLSchema#string

Sawsan Youssef

http://www.w3.org/2001/XMLSchema#string

Scott S Zamvil

http://www.w3.org/2001/XMLSchema#string

Stefan Nessler

http://www.w3.org/2001/XMLSchema#string

Thomas Prod'homme

http://www.w3.org/2001/XMLSchema#string

P2860

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Protein prenylation: molecular mechanisms and functional consequences

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.

Interferons in relapsing remitting multiple sclerosis: a systematic review.

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.

T cells with two functional antigen-specific receptors

P304

1037-1044

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI25805

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7234812

http://www.w3.org/2001/XMLSchema#string

P698

16543951

http://www.w3.org/2001/XMLSchema#string

P932

1401481

http://www.w3.org/2001/XMLSchema#string